zebrafish

Bloomberg for drug discovery

Zebrafish

Release 01Obesity and weight management, 26 Oct 2026

  1. The obesity program map.01
  2. Every code name, resolved.02
  3. Undisclosed mechanisms.03
  4. The China pipeline.04
  5. Incretins and after.05
  6. Method and label quality.06

A curated map of drug programs for biotech investors. Mechanism, modality, phase and developer for every program, with the evidence behind every label.

A translucent optical-disc case containing a dark iridescent disc on black. —R01
Plate ZF—R01David Rudnick / 2024 ↗

621 drug programs from 3,535 registered trials. One row per molecule, with code names, brands and INNs merged.

One seat, the whole map.

Seats are sold to biotech funds. Each seat opens the terminal, the exports and an analyst on call.

  1. No. 01TerminalScreen programs by mechanism, phase, modality, developer and country.
  2. No. 02ExportsThe program table and the trial-level evidence table as CSV.
  3. No. 03research@zebrafish.bioSeat requests and analyst questions.
Release
01, Obesity
Dated
26 Oct 2026
Programs
621
Trials read
3,535
Fields
27 per program
Source
ClinicalTrials.gov
Access
Seat holders